Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Handheld Fan Direction for Breathlessness in Chronic Heart and Lung Disease

6 de noviembre de 2026 actualizado por: Mohamed Fakhry Ahmed Salem, Alexandria University

Fan-to-Face Versus Fan-to-Leg Versus No Fan on Exertional Breathlessness and Exercise Capacity With Stable Chronic Cardiopulmonary Disease: A Mixed Method Three-Arm Randomized Controlled Trial

People with chronic heart failure or chronic lung disease (such as COPD or interstitial lung disease) often feel short of breath when they exert themselves. A handheld fan blowing air on the face may ease this feeling, but it is not clear whether the benefit lasts with longer home use, whether it depends on the direction of the airflow, or whether it works in patients with heart disease and in hot climates.

This study will compare three conditions in adults with stable chronic heart and/or lung disease who become breathless on exertion: (1) a handheld fan directed at the face, (2) a handheld fan directed at the leg, and (3) no fan (usual care). Participants will be randomly assigned (1:1:1) to one of the three groups. The two fan groups will use the fan at home for 12 weeks. The no-fan group will receive a fan after the final assessment. The person measuring outcomes will not know which group each participant is in.

The main outcome is breathlessness (Borg 0-10 scale) in the 5 minutes after a 6-minute walk test at week 12. Other outcomes include walking distance, recovery time, breathlessness severity and impact (Dyspnoea-12), functional class, global change in breathlessness, fan use and acceptability, and emergency visits or hospital admissions.

The study also includes interviews with about 24 to 30 participants from the three groups after week 12, to understand how the fan was used, how acceptable it was, and how heat and humidity affected it. Trial and interview findings will be analysed separately and then combined.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

129

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Alexandria, Egipto, 21511
        • Faculty of Nursing, Alexandria University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Adults with chronic heart failure and/or chronic lung disease (for example chronic obstructive pulmonary disease or interstitial lung disease) confirmed by a cardiologist or chest physician
  • Stable condition: heart failure NYHA class II to III, and no exacerbation of lung disease in recent weeks, confirmed with the treating specialist
  • Breathlessness on exertion, with an MRC dyspnoea grade and a Borg score after the 6-minute walk test at or above a minimum set in advance [FILL: e.g. Borg >= 3]
  • Stable medication, with no marked change in recent weeks [FILL: period set by the treating specialist]
  • Able to walk, answer the questionnaires and give written informed consent

Exclusion Criteria:

  • Acute heart failure, an acute exacerbation of lung disease, or a recent hospital admission
  • Another dominant cause of breathlessness (for example severe anemia, pulmonary embolism or neuromuscular disease)
  • Severe lung disease needing oxygen at rest
  • Unstable angina, recent myocardial infarction, or any condition that prevents walking or raises risk
  • Cognitive impairment that prevents responding, or inability to use the fan
  • Participation in another trial

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Fan-to-Face

Handheld battery-operated fan directed at the face whenever the participant feels breathless, for 12 weeks at home. Participants receive training and a teach-back check at week 0 and keep a daily diary. Usual care continues unchanged.

Battery-operated handheld fan (same model and speed in both fan arms) directed at the face at a distance of about 15 to 30 cm whenever the participant feels breathless, for a set time per use after training. Used at home for 12 weeks.

Experimental: Fan-to-Leg

Same handheld fan (same model and speed) directed at the leg at the same distance and for the same duration whenever the participant feels breathless, for 12 weeks at home. Training, teach-back, diary and usual care are the same as in the fan-to-face arm.

The same handheld fan directed at the leg at the same distance and for the same duration per use. Used at home for 12 weeks as an active comparator.

Sin intervención: No Fan

Usual care for the heart or lung disease for 12 weeks, with a daily diary of breathless episodes and the same visit and phone-call schedule. After the 6-minute walk test, participants rest seated for 5 minutes without a fan. A fan is offered after the week 12 assessment.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Breathlessness intensity (Borg CR10) after the 6-minute walk test
Periodo de tiempo: Week 12

Breathlessness rated on the Borg CR10 scale (0 = nothing at all, 10 = maximal; higher is worse) during the 5 minutes of seated recovery after a 6-minute walk test, with a fan (fan-to-face and fan-to-leg arms) or seated rest without a fan (no-fan arm). Rated at minutes 1, 3 and 5; the minute used for the primary analysis is [FIX BEFORE SUBMITTING]. The walk test is done without a fan in all arms.

Week 12

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
6-minute walk distance
Periodo de tiempo: Week 0 and week 12

Distance walked in 6 minutes.

Week 0 and week 12
Recovery time after exertion
Periodo de tiempo: Week 0 and week 12

Minutes from the end of the walk test until Borg breathlessness first returns to the pre-test value, asked every minute for 5 minutes (censored at 5 minutes).

Week 0 and week 12
Borg CR10 breathing discomfort
Periodo de tiempo: Week 0 and week 12

Borg CR10 rating of breathing discomfort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Week 0 and week 12
Dyspnoea-12 total score
Periodo de tiempo: Week 0 and week 12

12 breathlessness descriptors, each scored 0 to 3; total 0 to 36 (higher is worse), with physical (0 to 21) and affective (0 to 15) components.

Week 0 and week 12
Functional class
Periodo de tiempo: Week 0 and week 12

NYHA class (I to IV) in heart failure participants, and MRC dyspnoea grade (1 to 5) in all participants. Higher is worse.

Week 0 and week 12
Borg CR10 leg effort
Periodo de tiempo: Time Frame: Week 0 and Week 12

Borg CR10 rating of leg effort (0 to 10, higher is worse), assessed before and at the end of the 6-minute walk test.

Time Frame: Week 0 and Week 12

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Qualitative experience, acceptability and context
Periodo de tiempo: Within 7 days after the week 12 visit

Semi-structured interviews (30 to 45 minutes) with about 24 to 30 participants on how the fan was used, perceived mechanism, barriers, and effect of heat and humidity. Reflexive thematic analysis.

Within 7 days after the week 12 visit

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Mohamed Fakhry Ahmed Salem, PHD, Alexandria University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

11 de noviembre de 2026

Finalización primaria (Estimado)

3 de febrero de 2027

Finalización del estudio (Estimado)

10 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

2 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Publicado por primera vez (Actual)

12 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Otros números de identificación del estudio

  • FANCP-2026-01

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .